
Work Here?
Caidya is a global contract research organization that provides outsourced clinical development services for biopharmaceutical and medical device companies. It covers the full lifecycle from pre-IND strategy and early-phase development through late-stage trials, regulatory submissions, and post-marketing surveillance, delivered via flexible models like standalone projects, full-service partnerships, and functional service provider arrangements, supported by its Clarity data platform that offers near real-time trial visibility and compatibility with Medidata Rave and Veeva. Its competitive edge comes from the merged legacy of Clinipace and dMed Global, strong leadership under Dr. Lingshi Tan, a broad global footprint including North America and China, and an emphasis on data-driven, transparent trial delivery. The goal is to help clients bring therapies to market efficiently and compliantly through high-quality, scalable trial execution across global programs.
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$322.2M
Headquarters
Morrisville, North Carolina
Founded
2003
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$322.2M
Above
Industry Average
Funded Over
10 Rounds
Caidya, a global clinical research organisation, has appointed Michael Clay as chief operating officer. Clay will oversee global operational delivery, client engagement and execution strategy across the US, Europe and Asia-Pacific. Clay brings extensive experience leading global clinical programmes across more than 60 countries, with particular expertise in Asia-Pacific operations. Most recently, he served as senior vice president of Global Project Delivery at Fortrea, where he managed over 500 global clinical trials. The appointment strengthens Caidya's operational capabilities, particularly in China and the broader APAC region. Caidya operates in more than 20 countries and conducts studies across over 50 countries, focusing on complex therapeutic areas including oncology, haematology and rare diseases.
Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.
dMed-Clinipace, a Shangai, China- and Morrisville, NC-based global full-service Clinical Contract Research Organization (CRO), closed a US$50m Series C+ financing. The round was led by Springhill Fund, with participation from funds managed by Rock Springs Capital and Superstring Capital. They joined Series C lead investor Fidelity Management and Research Company LLC as well as other new […]
MORRISVILLE – Clinical research firm Clinipace, which recently merged with Shanghai-based dMed, has closed on $50 million in new funding from three primary backers.
SHANGHAI and MORRISVILLE, N.C., May 21, 2021 /PRNewswire/ -- Following the recent merger announcement of Shanghai -based dMed Global and NC-based Clinipace Incorporated, the combined company today announced the appointment of Simon Britton to the position of Chief Operating Officer (COO).
Find jobs on Simplify and start your career today
Industries
Data & Analytics
Consulting
Enterprise Software
Healthcare
Company Size
201-500
Company Stage
Growth Equity (Venture Capital)
Total Funding
$322.2M
Headquarters
Morrisville, North Carolina
Founded
2003
Find jobs on Simplify and start your career today